Esophageal Cancer

Overview
Epidemiology
Types
Pathophysiology (Barrett's Esophagus)
Risk Factors
Clinical Presentation
Diagnosis and Staging
Treatment
Prognosis
Key Research Papers
Connections
Featured Videos

1. Overview

Esophageal cancer is a malignancy arising from the cells lining the esophagus — the muscular tube, roughly 25 centimeters long, that carries food and liquid from the throat down to the stomach. It is a disease that often hides in plain sight: early tumors cause no symptoms, and by the time the most common warning sign — difficulty swallowing — appears, many patients already have locally advanced or metastatic disease. This late-presentation pattern is the central challenge in esophageal cancer care.

What makes esophageal cancer unusual among common gastrointestinal (GI) malignancies is that it is really two distinct diseases sharing one organ. Squamous cell carcinoma (SCC), arising from the flat cells lining the upper and middle esophagus, has dominated worldwide for centuries, driven by tobacco and alcohol. Adenocarcinoma (EAC), arising from gland cells in the lower esophagus, was rare before the 1970s and has now become the dominant type in the United States, United Kingdom, and much of Western Europe — one of the fastest-rising cancers in the developed world, fueled by the obesity epidemic and its companion condition, chronic gastroesophageal reflux disease (GERD).

Globally, esophageal cancer is the seventh most common cancer and the sixth leading cause of cancer death. Its overall five-year survival rate is about 22% in U.S. SEER (Surveillance, Epidemiology, and End Results) data, reflecting how frequently it is caught late. But that bleak average conceals meaningful variation: patients whose disease is still confined to the esophagus at diagnosis have five-year survival of 48.6% in those data, and the figures quoted for the earliest tumors (stage I) are higher. The challenge — and the opportunity — lies in closing the gap between early detection and the current reality of late diagnosis. Surveillance programs for Barrett's esophagus, the known precursor to EAC, aim to do exactly that. Meanwhile, immunotherapy is changing outcomes for patients with advanced disease in ways that would have been unimaginable a decade ago.

2. Epidemiology

In the United States, SEER estimates 22,530 new cases of esophageal cancer and 16,290 deaths from the disease for 2026 — a high case-fatality ratio that reflects late-stage presentation. Worldwide, over 600,000 new cases and more than 540,000 deaths are attributed to esophageal cancer annually, making it the sixth leading cause of cancer mortality globally.

The geographic split is striking. In the United States, United Kingdom, Australia, and Western Europe, adenocarcinoma now accounts for 60–70% of esophageal cancers, with incidence rising steadily since the 1970s. Squamous cell carcinoma remains dominant in the rest of the world — particularly in China, Iran, Central Asia, sub-Saharan Africa, and parts of South America. A narrow band sometimes called the "Esophageal Cancer Belt" stretching from northeastern China through central Asia to Iran has among the highest SCC rates on earth, in some regions exceeding 100 cases per 100,000 people annually, likely driven by hot-beverage consumption, nutritional deficiencies, and exposure to mycotoxins in stored grain.

Sex differences are pronounced. For adenocarcinoma, men are affected three to four times more often than women — one of the most skewed sex ratios of any common cancer. The leading explanation is the triple interaction between obesity, reflux, and Barrett's esophagus, all of which are more common and more severe in men. Visceral (abdominal) fat in particular increases intra-abdominal pressure and promotes reflux. For squamous cell carcinoma, the sex ratio is less extreme but still tilts male.

Race and ethnicity matter. EAC disproportionately affects white men. SCC in the United States affects Black patients at higher rates than white patients. Overall esophageal cancer mortality is higher in Black Americans, partly because of differential access to surveillance and early treatment.

The overall five-year survival rate is approximately 22% (22.2% in SEER data for 2016–2022), though this figure is heavily dragged down by late-stage diagnoses. Patients with localized disease at diagnosis have five-year survival of 48.6%; those with regional spread, 29.1%; those with distant metastatic disease, 5.3%. Improving survival means catching the disease earlier — and much of the surveillance science around Barrett's esophagus is built on exactly that goal.

3. Types

The two major histological types of esophageal cancer behave differently, arise in different locations, and require different approaches to treatment.

Esophageal Adenocarcinoma (EAC)

Esophageal adenocarcinoma arises in the lower third of the esophagus and the gastroesophageal junction (GEJ) — the zone where the esophagus meets the stomach. It almost always develops on the foundation of Barrett's esophagus (described in detail below), in which chronic acid reflux damages the normal squamous lining and triggers its replacement by glandular cells similar to the intestinal lining. This transformation is called intestinal metaplasia.

EAC's incidence has risen by roughly 600% in the United States since the late 1970s, a trajectory unique among major cancers. The main drivers are the twin epidemics of obesity and gastroesophageal reflux disease. Molecular profiling has identified several recurrent alterations: HER2 (ERBB2) amplification in approximately 15–20% of cases is clinically critical because it opens the door to HER2-targeted therapy with trastuzumab. Other common alterations include TP53 mutations, CDKN2A loss, and chromosomal instability. VEGF overexpression makes antiangiogenic drugs relevant. PD-L1 expression predicts response to immune-checkpoint inhibitors.

Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal squamous cell carcinoma arises from the flat squamous cells lining the upper and middle esophagus. It is the dominant subtype worldwide and in populations with high alcohol and tobacco use. The molecular landscape differs from EAC: TP53 mutations are present in over 70% of ESCC, and CCND1 amplification and CDKN2A deletion are characteristic. Unlike EAC, ESCC does not arise through a well-defined precursor lesion that is easily surveilled — high-grade squamous dysplasia exists but is not routinely screened for in most countries.

Important risk associations unique to SCC include achalasia (a motility disorder causing food stasis and mucosal irritation), the Plummer-Vinson syndrome (iron-deficiency anemia, dysphagia, and esophageal webs, predominantly in Scandinavian women), prior radiation therapy to the chest or neck, and very hot beverage consumption. The International Agency for Research on Cancer has classified drinking beverages above 65°C as a probable carcinogen (Group 2A) based largely on ESCC risk data.

Squamous cell carcinoma of the esophagus has historically been treated with neoadjuvant chemoradiotherapy followed by surgery, and this approach achieves particularly high rates of pathological complete response (pCR) compared with adenocarcinoma — a difference reflected in the CROSS trial results (49% pCR reported for SCC; 29%, or 47 of 161 patients, was the rate across all cell types).

Rarer subtypes include small cell carcinoma of the esophagus (treated like small cell lung cancer with platinum-based chemotherapy), adenosquamous carcinoma, and gastrointestinal stromal tumors (GISTs) arising in the esophageal wall.

4. Pathophysiology (Barrett's Esophagus)

Understanding esophageal adenocarcinoma requires understanding its precursor: Barrett's esophagus (BE). Barrett's esophagus is diagnosed in approximately 1–2% of the adult population in Western countries, and in up to 10–15% of people with chronic gastroesophageal reflux disease symptoms. It is the single most important risk factor for EAC.

How Barrett's forms. The normal esophagus is lined with stratified squamous epithelium — the same tough, flat-cell lining found in the mouth. When stomach acid and bile reflux repeatedly into the lower esophagus, this lining is damaged. In a subset of people, the repair mechanism goes awry: instead of restoring squamous cells, the body lays down a different type of cell, the columnar epithelium with goblet cells typical of the intestinal lining. This is intestinal metaplasia. On endoscopy, the affected segment appears salmon-pink rather than pale grey, replacing the normal squamocolumnar junction (the "Z-line") upward into the esophagus. Biopsies confirming goblet cells are required to make the diagnosis definitively under current U.S. guidelines.

The progression sequence. Barrett's esophagus exists on a spectrum of dysplasia — a measure of how abnormal the cells look under the microscope:

Non-dysplastic Barrett's esophagus (ND-BE): Intestinal metaplasia without nuclear atypia. The annual risk of progression to EAC is low — approximately 0.1–0.3% per year. Most people with ND-BE never develop cancer in their lifetime.
Low-grade dysplasia (LGD): Mild cellular atypia. Annual EAC risk approximately 0.5–1%. Current guidelines recommend either surveillance endoscopy every 6–12 months or endoscopic ablative therapy.
High-grade dysplasia (HGD): Severe cellular abnormality, essentially carcinoma in situ. Annual progression risk 6–19% without treatment. Endoscopic eradication therapy (EET) — radiofrequency ablation (RFA) combined with endoscopic mucosal resection (EMR) for visible nodules — is the standard approach. The landmark AIM Dysplasia trial (Shaheen et al., 2009) showed that RFA eradicated HGD in 81% of patients and significantly reduced progression to EAC compared with sham treatment.
Intramucosal adenocarcinoma (T1a): Cancer confined to the mucosal layer, without invasion of the submucosa or beyond. Lymph node metastasis risk is very low (<2%), making endoscopic resection curative in most cases.

Why surveillance matters. A patient with known BE who develops HGD and receives endoscopic eradication has outcomes dramatically better than a patient who first presents with symptoms of invasive EAC. The entire surveillance and ablation program for Barrett's is built on the premise that catching neoplastic progression early, while it is still endoscopically treatable, converts what would be a lethal disease into a curable one. This is the best case for screening in esophageal cancer — not population-wide screening (which is not recommended), but targeted surveillance in the population already known to have the precursor lesion.

Medicines tested in Barrett's esophagus. The AspECT trial (Jankowski et al., Lancet 2018; 2,557 people, median 8.9 years) measured a combined outcome of death, adenocarcinoma or high-grade dysplasia. High-dose esomeprazole, an acid blocker (40 mg twice daily), did better than low-dose (20 mg once daily; time ratio 1.27). Aspirin alone did not reach significance (time ratio 1.24, p=0.068), and high-dose esomeprazole plus aspirin had the strongest effect (time ratio 1.59). Serious treatment-related events were reported by 1% of participants. The American College of Gastroenterology 2022 guideline (Shaheen et al.) could not make recommendations on such chemoprevention because of insufficient data. That guideline also broadened accepted screening methods to include non-endoscopic ones and liberalized surveillance intervals for short-segment Barrett's esophagus.

For squamous cell carcinoma, the pathophysiological chain is less formalized: chronic mucosal injury from any of the above agents leads to squamous dysplasia, then carcinoma in situ, then invasive cancer. The timeline can be shorter than the BE-to-EAC sequence.

5. Risk Factors

The two histological subtypes have largely separate risk factor profiles, though tobacco use and obesity contribute to both.

Risk factors for esophageal adenocarcinoma (EAC):

Chronic gastroesophageal reflux disease. The cornerstone risk. Long-standing, frequent reflux symptoms increase EAC risk 5-fold; severe or nocturnal reflux may increase risk 11-fold or more.
Barrett's esophagus. The premalignant precursor; about 95% of EACs arise from BE.
Obesity, especially abdominal/central obesity. Visceral fat increases intra-abdominal pressure, worsens reflux, and promotes a pro-inflammatory metabolic milieu. Obesity independently increases EAC risk even after adjusting for gastroesophageal reflux disease symptoms.
Male sex. Men are three to four times more likely than women to develop EAC. The reasons relate to fat distribution and sex hormone differences in esophageal mucosal response to acid.
White race. EAC disproportionately affects white populations in Western countries.
Tobacco smoking. A moderate independent risk factor for EAC (though less dominant than for SCC).
Hiatal hernia. Promotes reflux and increases EAC risk independently. See hiatal hernia.
Low fruit and vegetable intake. Diets deficient in antioxidants may fail to counteract oxidative mucosal damage from acid exposure.

Risk factors for esophageal squamous cell carcinoma (ESCC):

Heavy alcohol consumption. The most powerful modifiable risk factor for SCC; risk scales with amount consumed. Acetaldehyde, the first metabolic product of alcohol, is a direct carcinogen.
Tobacco use. Synergistic with alcohol — the combination multiplies risk far beyond either factor alone. Cigarettes, pipe tobacco, chewing tobacco, and betel nut all increase SCC risk.
Achalasia. A motility disorder causing impaired esophageal emptying and food stasis; long-standing achalasia increases SCC risk approximately 16-fold.
Hot beverage consumption (above 65°C), including hot tea, mate, and coffee consumed at scalding temperatures. The International Agency for Research on Cancer (IARC) classifies this as a Group 2A probable carcinogen.
Nutritional deficiencies (vitamins A, C, E, zinc, selenium) common in high-incidence regions.
Plummer-Vinson syndrome (Patterson-Kelly syndrome): iron-deficiency anemia with esophageal webs; increases SCC risk particularly in the post-cricoid region.
Prior head and neck cancer or radiation. Field cancerization and radiation-induced mucosal damage increase SCC risk in the upper esophagus.
Caustic ingestion (lye or other corrosive agents): scar tissue in the esophagus dramatically increases SCC risk decades after injury.
Tylosis (palmoplantar keratoderma): a rare inherited disorder associated with near-100% lifetime SCC risk.

6. Clinical Presentation

The clinical hallmark of esophageal cancer is dysphagia — difficulty swallowing — and it is the symptom that most often drives patients to seek medical attention. The pattern is characteristic: dysphagia typically begins with solid foods (meat, bread) and progressively worsens to softer foods and eventually liquids as the tumor grows and narrows the esophageal lumen. This progression from solid to liquid dysphagia over weeks to months is almost always a red flag that hospitals treat as urgent.

The critical, hard truth about esophageal cancer symptoms is this: by the time dysphagia appears, the tumor has usually already occupied 50–75% of the esophageal lumen. Early esophageal cancer — the kind that is curable — is typically asymptomatic. It is found incidentally during Barrett's surveillance endoscopy or upper endoscopy for another indication. Patients who wait for symptoms before seeking evaluation are statistically unlikely to have early-stage disease.

Symptoms, from most to less common:

Progressive dysphagia — starts with solids, advances to liquids. The signature symptom of esophageal narrowing.
Unintentional weight loss — almost universal in symptomatic patients, from both reduced caloric intake and the metabolic burden of the cancer itself.
Odynophagia (pain with swallowing) — suggests ulceration of the tumor surface or involvement of periesophageal structures.
Regurgitation of undigested food, especially when lying down (food sits above the obstruction).
Chest pain or discomfort, particularly retrosternal (behind the breastbone), which may be confused with cardiac disease or gastroesophageal reflux disease.
Hoarseness — a warning sign of recurrent laryngeal nerve (RLN) invasion, indicating locally advanced disease extending to mediastinal structures. The left RLN loops around the aorta and is more commonly involved than the right.
Horner's syndrome (ptosis, miosis, anhidrosis on one side of the face) — from involvement of the cervical sympathetic chain; indicates advanced mediastinal extension.
Chronic cough or coughing when eating — may indicate a tracheoesophageal (TE) fistula, in which tumor erosion creates an abnormal connection between the esophagus and trachea/bronchi. A TE fistula is a serious, life-threatening complication requiring urgent management.
Hematemesis (vomiting blood) or melena (dark, tarry stools) from tumor bleeding.
Cervical lymphadenopathy — palpable swollen lymph nodes in the neck in proximal or SCC-type tumors.
Back pain — may indicate vertebral or paraaortic lymph node involvement.

Upper endoscopy (esophagogastroduodenoscopy, EGD) is the test that evaluates these symptoms definitively. A delay of even weeks can allow a resectable tumor to become unresectable.

7. Diagnosis and Staging

Diagnosis of esophageal cancer proceeds through endoscopic confirmation followed by comprehensive staging to determine resectability and guide treatment planning.

Diagnostic Evaluation

Barium esophagram (barium swallow) may be the first imaging test ordered when a patient presents with dysphagia. It can reveal characteristic findings such as a "rat-tail" narrowing (tapering stricture), an irregular filling defect, or a shelf-like obstruction. It is an inexpensive, low-risk initial test that helps localize the lesion and assess the degree of obstruction. However, it cannot provide tissue diagnosis and is not sufficient alone.

Upper endoscopy (EGD) with biopsy is the definitive diagnostic procedure. Direct visualization allows the endoscopist to see the tumor, estimate its length and location, and take multiple biopsies for histological confirmation. At least 6–8 biopsy samples from different areas of the lesion maximize diagnostic yield. EGD also evaluates the rest of the esophagus for synchronous lesions and assesses the gastric cardia for GEJ involvement.

Barrett's esophagus surveillance follows a risk-stratified protocol based on dysplasia grade:

Non-dysplastic BE: surveillance endoscopy every 3–5 years
Low-grade dysplasia: every 6–12 months, or endoscopic eradication therapy (preferred by many centers)
High-grade dysplasia: endoscopic eradication therapy (EET) with RFA ± EMR, or esophagectomy in selected cases
Intramucosal carcinoma (T1a): endoscopic resection (endoscopic mucosal resection or endoscopic submucosal dissection) is often curative

Staging

Once the diagnosis is confirmed, full staging is essential. Esophageal cancer is staged using the AJCC TNM system (Tumor depth, lymph Node involvement, distant Metastasis), with separate staging tables for SCC and adenocarcinoma reflecting their different prognostic behaviors.

Endoscopic ultrasound (EUS) is the most accurate modality for local staging. It determines the depth of tumor invasion (T stage) and evaluates periesophageal lymph nodes (N stage) with the option of fine-needle aspiration (FNA) biopsy. EUS is particularly critical for distinguishing T1 from T2–T3 tumors, which drives the decision between endoscopic versus surgical treatment.

Computed tomography (CT) scan of the chest, abdomen, and pelvis (with intravenous contrast) is standard for evaluating regional and distant lymph node involvement, assessing adjacent organ invasion, and detecting liver, lung, or adrenal metastases.

Positron emission tomography/computed tomography (PET-CT) (positron emission tomography combined with computed tomography) detects metabolically active tumor deposits and is especially valuable for identifying occult distant metastases not visible on computed tomography alone. The addition of positron emission tomography/computed tomography upstages approximately 10–20% of patients who would otherwise be considered for curative-intent surgery — sparing them from an operation that would not help them.

Diagnostic laparoscopy is used for tumors of the GEJ and cardia (Siewert types I–III) to rule out peritoneal metastases, which computed tomography and positron emission tomography/computed tomography can miss.

Bronchoscopy may be performed for tumors at or above the carina to assess tracheobronchial involvement before surgical planning.

Biomarker testing: For adenocarcinoma, HER2 (ERBB2) testing (immunohistochemistry [IHC] and/or fluorescence in situ hybridization [FISH]) is done because HER2-positive tumors are eligible for trastuzumab. PD-L1 combined positive score (CPS) guides the use of immune-checkpoint inhibitors. Comprehensive next-generation sequencing (NGS) panels are increasingly used to identify additional targetable alterations.

8. Treatment

Treatment of esophageal cancer is stage-dependent and requires a multidisciplinary team including gastroenterology, surgery, medical oncology, radiation oncology, nutritional support, and palliative care.

Early Disease: Endoscopic Therapy

For high-grade dysplasia and intramucosal adenocarcinoma (T1a), endoscopic eradication therapy (EET) is the standard of care and avoids the morbidity of major surgery:

Endoscopic mucosal resection (EMR): lifts and removes visible nodules or raised areas, providing tissue for histology. If EMR reveals submucosal invasion (T1b) or lymphovascular invasion, surgical assessment is triggered.
Radiofrequency ablation (RFA): uses controlled thermal energy delivered via a balloon or focal catheter to ablate flat Barrett's mucosa (HGD or LGD). The AIM Dysplasia trial demonstrated 81% complete eradication of HGD and 77% complete eradication of intestinal metaplasia with RFA.
Endoscopic submucosal dissection (ESD): en-bloc resection for larger lesions; more widely used in Asia than in the West.

Resectable Locoregional Disease: Neoadjuvant Therapy Followed by Surgery

For clinically staged T1b–T3, N0–N1 disease without distant metastasis, a standard of care in the United States and Europe has been neoadjuvant chemoradiotherapy followed by esophagectomy, based on the landmark CROSS trial. For adenocarcinoma, the ESOPEC trial described below reported longer survival with perioperative chemotherapy.

The CROSS trial (van Hagen et al., NEJM 2012; long-term results Shapiro et al., Lancet Oncology 2015) randomized patients with resectable esophageal or GEJ cancer to neoadjuvant carboplatin + paclitaxel with concurrent radiotherapy (41.4 Gy in 23 fractions) followed by surgery, versus surgery alone. Key results:

Pathological complete response (pCR) rate: 29% across all cell types (47 of 161 patients who had surgery after chemoradiotherapy), with 49% reported for ESCC
Median overall survival: 48 months vs. 24 months (neoadjuvant chemoradiotherapy vs. surgery alone); by cell type, 81.6 vs. 21.1 months for squamous cell carcinoma and 43.2 vs. 27.1 months for adenocarcinoma
R0 (complete) resection rate significantly higher in the neoadjuvant group: 92% vs. 69%

The CROSS regimen (carboplatin dosed to an area under the curve [AUC] of 2 + paclitaxel 50 mg/m² weekly x 5 with concurrent radiotherapy) became a global standard for resectable esophageal cancer.

Alternatively, for adenocarcinoma of the lower esophagus and GEJ, perioperative chemotherapy (without radiation) using the FLOT regimen (docetaxel, oxaliplatin, leucovorin, 5-fluorouracil) has demonstrated superiority over older epirubicin, cisplatin and fluorouracil (ECF) regimens and is widely used in European centers.

The two approaches compared in adenocarcinoma. ESOPEC (Hoeppner et al., NEJM 2025; 438 people with resectable esophageal adenocarcinoma) compared perioperative FLOT plus surgery with the CROSS regimen plus surgery. Three-year overall survival was 57.4% vs. 50.7% (hazard ratio 0.70), and serious adverse events occurred in 47.3% vs. 41.8%. Neo-AEGIS (Reynolds et al., Lancet Gastroenterology & Hepatology 2023; 362 people analyzed), which closed early after a futility analysis, found similar survival: 3-year overall survival 55% with perioperative chemotherapy (FLOT became an option only from 2018) vs. 57% with the CROSS regimen.

Immunotherapy around surgery. MATTERHORN (Janjigian et al., NEJM 2025; 948 people) studied gastric and gastroesophageal junction adenocarcinoma, not tumors of the esophagus itself. Adding durvalumab to FLOT raised 2-year event-free survival from 58.5% to 67.4% and complete response at surgery from 7.2% to 19.2%. Two-year overall survival was 75.7% vs. 70.4%, a difference that did not cross the trial's significance threshold at this analysis.

Watching closely instead of operating. SANO (van der Wilk et al., Lancet Oncology 2025; 309 people in 12 Dutch hospitals) studied people with no tumor detected on biopsy, ultrasound and PET-CT after chemoradiotherapy. Close surveillance, with surgery only if needed, gave 2-year overall survival of 74%, non-inferior to 71% with immediate surgery. The authors state that extended follow-up is required to know the long-term effect.

Surgical Approaches

Esophagectomy is one of the most complex operations in thoracoabdominal surgery, and high-volume centers are where it is most often performed. The main approaches include:

Ivor Lewis esophagectomy: right thoracotomy + laparotomy with intrathoracic anastomosis. Best for tumors of the middle and lower esophagus and GEJ.
McKeown (three-field) esophagectomy: right thoracotomy + laparotomy + left cervical incision with cervical anastomosis. Used for proximal and mid-esophageal tumors.
Transhiatal esophagectomy: laparotomy + cervical incision without formal thoracotomy; lower pulmonary complication rate but less complete lymphadenectomy.
Minimally invasive esophagectomy (MIE): thoracoscopic and laparoscopic approach. Randomized trials (TIME trial) show equivalent oncologic outcomes with significantly reduced pulmonary complications and shorter hospital stay compared to open surgery.

The stomach is the preferred conduit to reconstruct the alimentary tract after esophagectomy. Anastomotic leak, pneumonia, and delayed gastric emptying are the most feared early complications. Long-term, patients adapt to eating small, frequent meals and managing dumping syndrome.

HER2-Positive Adenocarcinoma

For HER2-positive (IHC 3+ or IHC 2+/FISH amplified) advanced EAC or GEJ adenocarcinoma, adding trastuzumab to first-line platinum-based chemotherapy improves overall survival. The ToGA trial (Bang et al., Lancet 2010) randomized HER2+ gastric/GEJ cancer patients to cisplatin + capecitabine/5-FU plus or minus trastuzumab. Trastuzumab improved median overall survival from 11.1 to 13.8 months (hazard ratio 0.74); in the subgroup with IHC 2+/FISH+ or IHC 3+, the benefit was larger (overall survival 16.0 vs. 11.8 months). Trastuzumab is now standard first-line therapy for HER2-positive disease.

Advanced and Metastatic Disease: Immunotherapy Combinations

The management of metastatic esophageal cancer was transformed by immunotherapy trials published between 2020 and 2021:

CheckMate 649 (Janjigian et al., Lancet 2021): Nivolumab + chemotherapy (oxaliplatin + capecitabine or FOLFOX, which is leucovorin, fluorouracil and oxaliplatin) versus chemotherapy alone in previously untreated gastric/GEJ/esophageal adenocarcinoma that was not HER2-positive. Nivolumab combination significantly improved overall survival in patients with CPS ≥5 (median overall survival 14.4 vs. 11.1 months), with significant improvement also reported in patients with CPS ≥1 and in all randomized patients. The trial authors call it a new standard first-line treatment for advanced gastric/GEJ/EAC.
CheckMate 577 (Kelly et al., NEJM 2021): Adjuvant nivolumab versus placebo in resected esophageal or GEJ cancer patients who had received neoadjuvant chemoradiotherapy and did NOT achieve pCR. Nivolumab doubled disease-free survival (22.4 vs. 11.0 months). Now standard adjuvant therapy for patients with residual disease after neoadjuvant chemoradiotherapy and esophagectomy.
KEYNOTE-590 (Sun et al., Lancet 2021): Pembrolizumab + cisplatin + 5-fluorouracil versus chemotherapy alone in first-line treatment of locally advanced/metastatic ESCC or EAC. Pembrolizumab combination significantly improved overall survival: 12.4 vs. 9.8 months in all patients, 12.6 vs. 9.8 months in ESCC, and 13.9 vs. 8.8 months in ESCC with PD-L1 CPS ≥10. Pembrolizumab is now approved for first-line treatment of ESCC in combination with chemotherapy.
CheckMate 648 (Doki et al., NEJM 2022; 970 people with advanced squamous cell carcinoma): Nivolumab + chemotherapy versus chemotherapy alone. Median overall survival was 13.2 vs. 10.7 months in all patients and 15.4 vs. 9.1 months when tumor-cell PD-L1 was 1% or higher. Severe (grade 3 or 4) treatment-related side effects occurred in 47% vs. 36%.
Ramucirumab + paclitaxel remains an important second-line option regardless of PD-L1 status, based on the RAINBOW trial.

Palliative Interventions

For patients with unresectable disease, restoring the ability to swallow is a primary quality-of-life goal. Self-expanding metal stents (SEMS) placed endoscopically across the obstructing tumor provide rapid relief of dysphagia. Palliative radiotherapy can reduce bleeding and improve swallowing in selected patients. Nutritional support via percutaneous endoscopic gastrostomy (PEG) or jejunostomy feeding tube is often needed when oral intake is insufficient to maintain weight.

9. Prognosis

Prognosis in esophageal cancer is strongly tied to stage at diagnosis. Because most patients present with locally advanced or metastatic disease, the overall picture remains sobering. However, outcomes are genuinely improving at every stage.

Five-year relative survival in U.S. SEER data (2016–2022): localized 48.6%, regional 29.1%, distant 5.3%, all stages 22.2%.

Approximate five-year survival figures quoted by anatomic stage (SEER does not report these stages):

Stage I (localized, T1N0M0): approximately 75–80%
Stage II (locally advanced, T2–T3N0 or T1–T2N1): approximately 30–40%
Stage III (locally advanced with nodal involvement): approximately 15–20%
Stage IVA (regional/distant nodal metastasis): approximately 5–10%
Stage IVB (distant organ metastases): less than 5%

Pathological complete response (pCR) after neoadjuvant chemoradiotherapy is one of the strongest prognostic factors available. Patients who achieve pCR in the CROSS trial had markedly prolonged survival. The CROSS 10-year report (Eyck et al., Journal of Clinical Oncology 2021) gives figures for the whole treatment groups rather than the pCR group: overall survival 38% with chemoradiotherapy plus surgery vs. 25% with surgery alone (hazard ratio 0.70). This is why CheckMate 577 adjuvant nivolumab specifically targets the non-pCR population: their residual disease after surgery confers meaningfully worse prognosis, and nivolumab offers them an additional treatment tool.

Factors associated with better outcomes include: early stage at diagnosis, pCR after neoadjuvant therapy, R0 (microscopically clear margins) resection, absence of lymphovascular invasion, HER2-positive status (access to targeted therapy), high PD-L1 expression (immunotherapy benefit), treatment at high-volume centers, and adequate nutritional status throughout therapy.

For patients with advanced disease who are not surgical candidates, modern first-line immunotherapy-chemotherapy combinations have extended median overall survival to 13–16 months for selected populations, compared with 9–11 months with chemotherapy alone just a decade ago. While these numbers are not cure, they represent meaningful prolongation and, importantly, improved quality of life through better disease control.

Key Research Papers

The following studies represent foundational and practice-changing work in esophageal cancer. Each PMID link opens the abstract on PubMed.

Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results. Lancet Oncol. 2015;16(9):1090–1098. — PubMed PMID: 26254683
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA). Lancet. 2010;376(9742):687–697. — PubMed PMID: 20728210
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. — PubMed PMID: 34102137
Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (CheckMate 577). N Engl J Med. 2021;384(13):1191–1203. — PubMed PMID: 33789008
Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. — PubMed PMID: 34454674
Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med. 2014;371(9):836–845. — PubMed PMID: 25162890
Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia (AIM Dysplasia). N Engl J Med. 2009;360(22):2277–2288. — PubMed PMID: 19474425
Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499–2509. — PubMed PMID: 25539106
Thrift AP. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol. 2016;41:88–95. — PubMed PMID: 26851752
Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–2252. — PubMed PMID: 14657432
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer (MAGIC). N Engl J Med. 2006;355(1):11–20. — PubMed PMID: 16822992
Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, Version 2.2019. J Natl Compr Canc Netw. 2019;17(7):855–883. — PubMed PMID: 31319389
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084. — PubMed PMID: 22646630
Eyck BM, van Lanschot JJB, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39(18):1995–2004. — PubMed PMID: 33891478
Hoeppner J, Brunner T, Schmoor C, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med. 2025;392(4):323–335. — PubMed PMID: 39842010
Reynolds JV, Preston SR, O'Neill B, et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):1015–1027. — PubMed PMID: 37734399
Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–462. — PubMed PMID: 35108470
Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393(3):217–230. — PubMed PMID: 40454643
van der Wilk BJ, Eyck BM, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2025;26(4):425–436. — PubMed PMID: 40112851
Jankowski JAZ, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392(10145):400–408. — PubMed PMID: 30057104
Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. Am J Gastroenterol. 2022;117(4):559–587. — PubMed PMID: 35354777
National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Esophageal Cancer. — seer.cancer.gov/statfacts/html/esoph.html

PubMed Topic Searches

Back to Table of Contents

Connections